Is niraparibabiraterone tablets covered by medical insurance?

Niraparib Abiraterone Tablets (Akeega) is an anti-tumor compound preparation that has attracted much attention in recent years. It was developed by Johnson & Johnson (Janssen) and consists of the PARP inhibitor niraparib and the CYP17 enzyme inhibitor abiraterone acetate. acetate) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA gene mutations. Its mechanism of action is to achieve a stronger anti-cancer synergistic effect by dually blocking androgen production and DNA repair functions. Especially for patients with BRCA1/2 mutation-positive mCRPC, this drug shows a better survival advantage than single-agent abiraterone.

Currently, niraparibabiraterone tablets have been approved for marketing in the United States, the European Union, Japan and other countries or regions, and will be approved for marketing in China in the second half of 2024. Although this landmark development provides domestic patients with access to cutting-edge international drugs, as of now, niraparib and abiraterone tablets have not been included in the national medical insurance drug list. Due to the short time the drug has been on the market, the medical insurance negotiation process is still in the evaluation or preparation stage, and there is still no clear public information on its specific pricing, reimbursement ratio and access methods. According to international market price estimates, the price of this drug is on the high side. If it is used entirely at one's own expense, it may put greater financial pressure on patients.

According to the medical insurance access path for similar new drugs in the past, it generally needs to be on the market for more than one year, with real-world data and domestic efficacy and safety evaluation before it can enter the next round of national medical insurance negotiations. If it can prove its clinical efficacy advantages and significant patient benefits, combined with the country's encouragement policy for innovative cancer drugs, there is a certain possibility that Akeega will be included in medical insurance in the future. At the same time, some provinces and municipalities may give priority to early coverage through "local temporary medical insurance" or special major disease coverage.

Reference materials:https://www.drugs.com/akeega.html